SOPHiA GENETICS SA·4

Jun 22, 4:01 PM ET

HIBBS KATHY L 4

Research Summary

AI-generated summary

Updated

SOPH Director Kathy Hibbs Receives RSUs and Options Worth $265K

What Happened Kathy L. Hibbs, a director of SOPHiA GENETICS SA (SOPH), was granted equity awards on June 18, 2026: 19,724 restricted stock units (RSUs) and 28,818 derivative awards (share options), each shown at $5.46 per share. The RSU grant is valued at $107,693 and the derivative award at $157,346, for a combined grant value of approximately $265,039. These are awards (not purchases or sales) and represent compensation/retention incentives rather than open‑market buying or selling.

Key Details

  • Transaction date: June 18, 2026; Form 4 filed June 22, 2026 (within the standard two-business-day reporting window).
  • Awards: 19,724 RSUs @ $5.46 = $107,693; 28,818 derivative awards @ $5.46 = $157,346; total 48,542 shares equivalent ≈ $265,039.
  • Vesting: Both awards vest 100% as of the issuer’s next scheduled annual meeting of shareholders, subject to Hibbs’ continued service (per footnotes).
  • Shares owned after transaction: not reported in the provided data.
  • Footnotes: F1 = RSU grant (each RSU converts to one ordinary share upon vesting). F2 = share option/derivative grant; vests fully at next annual meeting, subject to service.

Context RSUs and option grants are common director compensation and are contingent on future vesting (these do not represent immediate share sales). Because the awards vest 100% at the next annual meeting subject to continued service, they function primarily as retention/compensation incentives. There is no indication in this filing of a simultaneous sale (cashless exercise) or tax‑withholding disposition.